Astrazeneca plc EBIT

The latest EBIT for AZN is $15B as of September 2026. That compares with $13B in the prior-year period — up 15.1% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Astrazeneca plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, AZN's EBIT moved from $13B to $15B — a 15.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Astrazeneca plc's operating scale or balance-sheet position.

Against Healthcare companies, AZN currently prints $15B for EBIT, while the sector average sits near $99B. That is roughly 84.9% below the sector mean. Large gaps often invite a closer look at Astrazeneca plc's growth, margins, and balance sheet.

A EBIT figure of $15B for AZN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting AZN's EBIT ($15B), review year-over-year change from $13B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.